Resources

This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject™ injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.

This brief summarizes the strategic demand models developed by PATH and the Futures Institute for the injectable contraceptive depo-subQ provera 104™ in the Uniject™ injection system (depo-subQ in Uniject) in Kenya, Malawi, Pakistan, Rwanda, and Senegal. These models will help inform global and country introduction planning for depo-subQ in Uniject.

This fact sheet provides an overview of the impact that global and national investment have had in the fight against malaria, with an emphasis on the importance of US support for the President’s Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

This report provides an overview of Nicaragua's health system and diagnostic needs. It is supported by individual case studies on Chagas disease, dengue, and malaria in Nicaragua. These studies focus on several factors influencing the health care system in Nicaragua, including recent trends, regional and national control strategies, financing and partnerships, and the unmet clinical needs associated with each illness.

The cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel offers an attractive target for developing a novel antisecretory to treat infectious diarrhea because it is the primary driver of secretion in cases of diarrhea caused by cholera. iOWH032 is a synthetic CFTR inhibitor that has been studied for this indication.